Hyderabad: Dr Reddy’s Laboratories Ltd on Thursday said it has entered into a strategic collaboration with US-based biotechnology company Amgen Inc. to market and distribute three of Amgen’s medicines in India in the areas of oncology and cardiology.

Under the terms of the collaboration, Dr Reddy’s shall seek regulatory and commercial approval to launch cancer drugs Kyprolis and Blincyto and cardiovascular drug Repatha in India.

The collaboration leverages the capabilities of both companies, combining three of Amgen’s innovative therapies with Dr Reddy’s understanding of patient and physician needs in India, the firm said in a statement.

Kyprolis or carfilzomib was approved by the US Food and Drug Administration (FDA) in July, in combination with chemotherapy drug lenalidomide and dexamethasone, for the treatment of patients with relapsed multiple myeloma and who have received one to three prior lines of therapy.

Kyprolis is also indicated under FDA accelerated approval as a single agent for the treatment of patients with multiple myeloma.

Multiple myeloma is a form of blood cancer that arises from plasma cells and usually grows in bone marrow.

Blincyto or blinatumomab is monoclonal antibody used for the treatment of Leukemia, a cancer of the white blood cells. Blincyto was approved by the FDA in 2014.

Repatha or evolocumab, which was approved by the European Commission in July, is used for the treatment of patients with uncontrolled cholesterol despite taking maximum doses of statins or for those who cannot take statins and require additional intensive low-density lipoprotein cholesterol (LDL-C) reduction. Elevated LDL-C or bad cholesterol is recognized as a major risk factor for cardiovascular disease.

“We are excited about our strategic collaboration with an innovation powerhouse like Amgen and look forward to making their innovative medicines accessible to Indian patients," said Alok Sonig, executive vice-president and head of India business and global business development of Dr Reddy’s.

“Addressing significant unmet needs of patients in oncology and cardiovascular are key areas in India and, therefore, a priority for us at Dr Reddy’s," Sonig said.

“We are pleased to be joining forces with Dr Reddy’s Laboratories in order to make Amgen’s innovative medicines available to patients in India," said Penny Wan, vice-president and general manager, Japan and Asia Pacific region, Amgen.

Shares of Dr. Reddy’s gained as much as 3% and were trading at Rs4,285.80 at 12:26pm on BSE, while the benchmark Sensex declined 0.04% and was trading at 28,211.70 points.

My Reads Logout